Macular Degeneration Treatment Market Size
| Study Period | 2021 - 2029 |
| Market Size (2024) | USD 15.47 Billion |
| Market Size (2029) | USD 23.29 Billion |
| CAGR (2024 - 2029) | 8.51 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Macular Degeneration Treatment Market Analysis
The Macular Degeneration Treatment Market size is estimated at USD 15.47 billion in 2024, and is expected to reach USD 23.29 billion by 2029, growing at a CAGR of 8.51% during the forecast period (2024-2029).
The COVID-19 pandemic had potential economic impact and implications for most sectors, including the pharmaceutical and biotech industries. For instance, according to a research study published in the SN Comprehensive Clinical Medicine Journal in October 2020, the number of clinic visits for intravitreal injections (IVI) in the treatment of macular degeneration during one month from March 15 to April 14 of 2020 was compared to a similar time period in each of the last four years. The study demonstrated a decrease in clinic visits for intravitreal injections (IVI) compared with the same 4-week interval in the four previous years, and a total of 636 eyes received injections during a 4-week period of the COVID-19 outbreak in the Retina Clinic, Israel, in 2020, as compared to 995 injections in 2019. However, the easing of norms and the start of vaccination programs led to a recovery in the macular degeneration market.
The major factors attributing to the growth of the macular degeneration treatment market are the increasing burden of retinal disorders, the upsurge in the geriatric population, and an increase in research and development investments.
The increasing burden of retinal disorders is driving the market's growth. For instance, according to a research article published in the British Journal of Ophthalmology in August 2020, in Europe, age-related macular degeneration (AMD) is the main cause of visual impairment and blindness. About 67 million people in Europe are affected by age-related macular degeneration (AMD), and due to population aging, this number is expected to increase by 15% until 2050. As per the statistics, the increasing number of individuals with retinal disorders is directly proportional to market growth. Thus, the increasing burden of such disorders is driving the demand for macular degeneration treatment, which is further contributing to market growth.
Moreover, increasing research and development (R&D) and increasing clinical trials are other major factors for market growth. For instance, in November 2022, 4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, announced interim clinical data from cohort 1 of the Phase I/II clinical trial of intravitreal 4D-150 for wet AMD. The data focused on safety, tolerability, aflibercept transgene expression, and anti-VEGF clinical activity of the 4D-150 genetic medicine in patients enrolled in Cohort 1. Moreover, in January 2021, Novartis AG started a phase III clinical trial to evaluate the efficacy and safety of brolucizumab in patients with neovascular age-related macular degeneration. Such developments are fueling the growth of the macular degeneration market.
However, the increasing use of off-label drugs and lack of awareness regarding the disease are the major restraints on the growth of the market.
Macular Degeneration Treatment Market Trends
This section covers the major market trends shaping the Macular Degeneration Treatment Market according to our research experts:
Wet Age-related Macular Degeneration is Expected to Hold Significant Market Share Over the Forecast Period
By type, wet macular degeneration is anticipated to hold a significant share. Wet macular degeneration is the initiation of a typical growth of blood vessels beneath the retina. These overgrown blood vessels drip blood, which impedes the clarity of central vision and leads to macular degeneration.
As age-related macular degeneration is the most common cause of severe loss of eyesight among people over 50 years of age, the rising geriatric population all over the world is creating a high level of demand in the wet macular degeneration market. For instance, as per the World Population Prospects 2022, the share of the global population aged 65 years or older is projected to rise from 10% in 2022 to 16% in 2050. By 2050, the number of persons aged 65 or over worldwide is projected to be more than twice the number of children under age 5 and about the same as the number of children under age 12. The above statistics represent the high demand for products for the treatment of wet macular degeneration globally in the future.
Increasing research and development activities in the development of new products are also boosting market growth. For instance, in November 2022, CLS-AX demonstrated positive results in the Phase I/IIa OASIS clinical trial in neovascular wet age-related macular degeneration. CLS-AX (axitinib injectable suspension) met the trial's primary endpoint by demonstrating a positive safety profile at all doses and time points in 27 participants in four cohorts. Such studies are expected to boost the growth of the segment over the forecast period.
The market players adopted various strategies, such as product launches, collaborations, developments, acquisitions, mergers, and expansions, to increase their market share. For instance, in November 2022, STADA Arzneimittel AG and Xbrane Biopharma AB announced that the European Commission granted marketing authorization for Ximlici (ranibizumab), a biosimilar to Genentech's Lucentis. Silica is an anti-VEGF (vascular endothelial growth factor) for the treatment of retinal vascular disorders and has been approved by the European Union (EU) for the treatment of wet age-related macular degeneration (wet AMD). Hence, owing to the factors mentioned above, it is expected to drive the segment's growth over the forecast period.
North America Dominates the Market and is Expected to do Same in the Forecast Period
Some of the factors driving market growth in the North American region include the increasing burden of the geriatric population and age-related macular degeneration, the presence of key market players, and increasing research and development activities.
According to a research study published in Nature Medicine in August 2020, patients with age-related macular degeneration (AMD) who become infected with SARS-CoV-2 are at higher risk of developing severe complications, including requiring supplemental oxygen and death. Furthermore, the American Macular Degeneration Foundation (AMDF) in the United States disseminated this information to warn age-related macular degeneration (AMD) patients and eye care practitioners about the potential risk.
Advanced age-related macular degeneration is considered a leading cause of irreversible blindness and visual impairment across the world. Thus, the increasing burden of age-related macular degeneration is fueling market growth.
According to Canadian Ophthalmological Society data updated in February 2021, wet age-related macular degeneration is one of the major causes of vision loss in people over 65. As per the same source, at least one out of four Canadians may be diagnosed with macular degeneration by 2032.
Furthermore, beneficial government initiatives, an increase in the number of research partnerships, and the presence of the key market players, coupled with recent product launches, are anticipated to boost the growth of the market in the North American region. For instance, in October 2021, Roche received approval from the United States Food and Drug Administration for Susvimo (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for wet age-related macular degeneration (nAMD) in patients who have previously responded to at least two anti-vascular endothelial growth factors (VEGF) injections.
So, based on the things we've talked about so far, we expect the market in the region to grow a lot over the next few years.
Macular Degeneration Treatment Industry Overview
The macular degeneration treatment market is moderately competitive. However, mid-size to small companies are increasing their market presence with product innovations by introducing new products. Some companies include F Hoffmann-La Roche Ltd, Novartis AG, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., and Pfizer Inc., among others.
Macular Degeneration Treatment Market Leaders
-
Novartis AG
-
Bausch Health Companies Inc.
-
REGENXBIO Inc.
-
F Hoffmann-La Roche Ltd
-
Regeneron Pharmaceuticals Inc.
*Disclaimer: Major Players sorted in no particular order
Macular Degeneration Treatment Market News
- In November 2022, IVERIC bio, Inc. submitted the first part of its NDA to the US FDA for a rolling review of avacincaptad pegol a novel investigational complement C5 inhibitor, for the treatment of geographic atrophy (GA) secondary to Age-Related Macular Degeneration (AMD).
- In November 2022, The European Commission granted marketing authorization for Ximluci, the third ranibizumab biosimilar to be approved in the European Union. The product was developed through a partnership between STADA Arzneimittel and Xbrane Biopharma and is expected to launch in early 2023.
Macular Degeneration Treatment Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Burden of Retinal Disorders
- 4.2.2 Upsurge in the Geriatric Population
- 4.2.3 Increase in Research and Development Investments
-
4.3 Market Restraints
- 4.3.1 Increasing Use of Off-label Drugs
- 4.3.2 Lack of Awareness Regarding AMD
-
4.4 Industry Attractiveness - Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Buyers/Consumers
- 4.4.2 Bargaining Power of Suppliers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Value By Size - USD Million)
-
5.1 By Type
- 5.1.1 Dry Age-related Macular Degeneration
- 5.1.2 Wet Age-related Macular Degeneration
-
5.2 By Stage of Disease
- 5.2.1 Early-stage AMD
- 5.2.2 Intermediate AMD
- 5.2.3 Late-stage AMD
-
5.3 By Treatment Type
- 5.3.1 Drug
- 5.3.1.1 Anti-vascular Endothelial Growth Factor
- 5.3.1.2 Dietary Supplements
- 5.3.1.3 Other Drugs
- 5.3.2 Devices
- 5.3.2.1 Glasses
- 5.3.2.2 Contact Lenses
- 5.3.2.3 Other Devices
- 5.3.3 Surgery
- 5.3.3.1 Laser Surgery
- 5.3.3.2 Other Surgeries
-
5.4 By Route of Administration
- 5.4.1 Intravenous Route
- 5.4.2 Intravitreal Route
-
5.5 By Sales Channel
- 5.5.1 Ambulatory Surgical Centers
- 5.5.2 Hospitals
- 5.5.3 Other Sales Channels
-
5.6 Geography
- 5.6.1 North America
- 5.6.1.1 United States
- 5.6.1.2 Canada
- 5.6.1.3 Mexico
- 5.6.2 Europe
- 5.6.2.1 Germany
- 5.6.2.2 United Kingdom
- 5.6.2.3 France
- 5.6.2.4 Italy
- 5.6.2.5 Spain
- 5.6.2.6 Rest of Europe
- 5.6.3 Asia-Pacific
- 5.6.3.1 China
- 5.6.3.2 Japan
- 5.6.3.3 India
- 5.6.3.4 Australia
- 5.6.3.5 South Korea
- 5.6.3.6 Rest of Asia-Pacific
- 5.6.4 Middle-East and Africa
- 5.6.4.1 GCC
- 5.6.4.2 South Africa
- 5.6.4.3 Rest of Middle-East and Africa
- 5.6.5 South America
- 5.6.5.1 Brazil
- 5.6.5.2 Argentina
- 5.6.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 F Hoffmann-La Roche Ltd
- 6.1.2 Novartis AG
- 6.1.3 Pfizer Inc.
- 6.1.4 Panoptica
- 6.1.5 Bausch Health Companies Inc.
- 6.1.6 Regeneron Pharmaceuticals Inc.
- 6.1.7 Aerie Pharmaceutical Inc.
- 6.1.8 REGENXBIO Inc.
- 6.1.9 Bayer AG
- 6.1.10 Lineage Cell Therapeutics
- 6.1.11 Ocugen Inc.
- 6.1.12 Clover Therapeutics
- 6.1.13 ONL Therapeutics
- 6.1.14 MeiraGTx
- 6.1.15 Oxurion
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityMacular Degeneration Treatment Industry Segmentation
As per the scope of the report, macular degeneration is a retinal disorder affecting older people. The early stages of the disease (early and intermediate AMD) are generally asymptomatic, and they gradually progress to the late stages of the disease, which may cause severe visual loss. Type (Dry Age-Related Macular Degeneration and Wet Age-Related Macular Degeneration), Stage of Disease (Early-stage AMD, Intermediate AMD, and Late-stage AMD), Treatment Type (Drug, Devices, Surgery), Route of Administration (Intravenous Route and Intravitreal Route), Sales Channel (Ambulatory Surgical Centers, Hospitals, and Other Sales Channels), and Geography (North America, Europe, Asia). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Type | Dry Age-related Macular Degeneration | |
| Wet Age-related Macular Degeneration | ||
| By Stage of Disease | Early-stage AMD | |
| Intermediate AMD | ||
| Late-stage AMD | ||
| By Treatment Type | Drug | Anti-vascular Endothelial Growth Factor |
| Dietary Supplements | ||
| Other Drugs | ||
| By Treatment Type | Devices | Glasses |
| Contact Lenses | ||
| Other Devices | ||
| By Treatment Type | Surgery | Laser Surgery |
| Other Surgeries | ||
| By Route of Administration | Intravenous Route | |
| Intravitreal Route | ||
| By Sales Channel | Ambulatory Surgical Centers | |
| Hospitals | ||
| Other Sales Channels | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle-East and Africa | GCC |
| South Africa | ||
| Rest of Middle-East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Macular Degeneration Treatment Market Research FAQs
How big is the Macular Degeneration Treatment Market?
The Macular Degeneration Treatment Market size is expected to reach USD 15.47 billion in 2024 and grow at a CAGR of 8.51% to reach USD 23.29 billion by 2029.
What is the current Macular Degeneration Treatment Market size?
In 2024, the Macular Degeneration Treatment Market size is expected to reach USD 15.47 billion.
Who are the key players in Macular Degeneration Treatment Market?
Novartis AG, Bausch Health Companies Inc., REGENXBIO Inc., F Hoffmann-La Roche Ltd and Regeneron Pharmaceuticals Inc. are the major companies operating in the Macular Degeneration Treatment Market.
Which is the fastest growing region in Macular Degeneration Treatment Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Macular Degeneration Treatment Market?
In 2024, the North America accounts for the largest market share in Macular Degeneration Treatment Market.
What years does this Macular Degeneration Treatment Market cover, and what was the market size in 2023?
In 2023, the Macular Degeneration Treatment Market size was estimated at USD 14.26 billion. The report covers the Macular Degeneration Treatment Market historical market size for years: 2021, 2022 and 2023. The report also forecasts the Macular Degeneration Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Macular Degeneration Treatment Industry Report
The Juvenile Macular Degeneration Market is segmented by type, stage of disease, treatment type, route of administration, sales channel, and geography. The market analysis includes a detailed review of the market share and market size for each segment. The industry report provides an in-depth industry analysis, offering insights into market trends and market growth. The market forecast outlook extends to the future, while the historical overview provides context for the current market dynamics.
The industry reports highlight the leading market leaders and their strategies in the macular degeneration treatment sector. The market segmentation covers various treatment types, including drugs, devices, and surgery, as well as different routes of administration such as intravenous and intravitreal routes. The sales channels analyzed include ambulatory surgical centers, hospitals, and other sales channels across diverse geographic regions like North America, Europe, Asia-Pacific, Middle-East and Africa, and South America.
The report example and report PDF provide valuable industry information and market data, essential for understanding the market outlook and industry trends. The market value and market review sections offer a comprehensive overview of the industry's current status and future predictions. The research companies involved in the market research contribute to the detailed industry statistics and industry size, ensuring a thorough understanding of the market dynamics.
Overall, this industry research offers a robust foundation for understanding the macular degeneration treatment market, with a focus on growth rate, market forecast, and industry outlook. The market overview and industry sales sections provide a clear picture of the market's potential and the key factors driving market growth.
